Cleavable lipids
AssigneeTranslate Bio, Inc.
InventorsBraydon Charles Guild, Michael Heartlein, Frank DeRosa, Jerry Chi Zhang
Life of this patent
Estimating the term…
Abstract
Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.
Claims10
A lyophilized pharmaceutical composition comprising a lipid nanoparticle and a lyoprotectant that is sucrose,
- wherein the lipid nanoparticle comprises:
- mRNA;
- a cationic lipid,
- a PEG-modified lipid that is DMG-PEG2000,
- a non-cationic lipid selected from the group consisting of DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine), DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine), DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol)), DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine), DLPE (1,2-dilauroyl-sn-glycero-3-phosphoethanolamine), DPPS (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine), and
- a helper lipid that is cholesterol.
A lyophilized pharmaceutical composition comprising a lipid nanoparticle and a lyoprotectant that is sucrose,
- wherein the lipid nanoparticle comprises
- mRNA,
- a cationic lipid,
- a PEG-modified lipid that is DMG-PEG2000,
- a non-cationic lipid that is 1,2-dioleyl-sn-glycero-3-phosphoethanolamine (DOPE), and
- a helper lipid that is cholesterol.
Dependencies are inferred from the claim text.